| Literature DB >> 25469820 |
Shuhei Sakata1, Shinya Hayashi, Takaaki Fujishiro, Kohei Kawakita, Noriyuki Kanzaki, Shingo Hashimoto, Kenjiro Iwasa, Nobuaki Chinzei, Shinsuke Kihara, Masahiko Haneda, Takeshi Ueha, Takayuki Nishiyama, Ryosuke Kuroda, Masahiro Kurosaka.
Abstract
Eicosapentaenoic acid (EPA) is an antioxidant and n-3 polyunsaturated fatty acid that reduces the production of inflammatory cytokines. We evaluated the role of EPA in chondrocyte apoptosis and degeneration. Normal human chondrocytes were treated with EPA and sodium nitroprusside (SNP). Expression of metalloproteinases (MMPs) was detected by real-time polymerase chain reaction (PCR) and that of apoptosis-related proteins was detected by western blotting. Chondrocyte apoptosis was detected by flow cytometry. C57BL/6J mice were used for the detection of MMP expression by immunohistochemistry and for investigation of chondrocyte apoptosis. EPA inhibited SNP-induced chondrocyte apoptosis, caspase 3 and poly(ADP-ribose) polymerase cleavage, phosphorylation of p38 MAPK and p53, and expression of MMP3 and MMP13. Intra-articular injection of EPA prevented the progression of osteoarthritis (OA) by inhibiting MMP13 expression and chondrocyte apoptosis. EPA treatment can control oxidative stress-induced OA progression, and thus may be a new approach for OA therapy.Entities:
Keywords: chondrocyte; eicosapentaenoic acid; matrix metalloproteinase; osteoarthritis
Mesh:
Substances:
Year: 2014 PMID: 25469820 DOI: 10.1002/jor.22767
Source DB: PubMed Journal: J Orthop Res ISSN: 0736-0266 Impact factor: 3.494